Trius Therapeutics | The Medical Letter on Drugs and Therapeutics | Journal of Pharmacology and Experimental Therapeutics | Journal of Manipulative and Physiological Therapeutics | Esperion Therapeutics | Acorda Therapeutics |
Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation.